Episode Details

Morgan Stanley just pulled a surprising move—boosting Charles River Labs while cutting IQVIA Holdings—despite both firms competing in the same contract research space. The twist? IQVIA is buying lab assets Charles River is selling, a move that could give IQVIA new European labs. Morgan Stanley sees rising biotech funding fueling demand for Charles River’s streamlined, core services, while questioning IQVIA’s growth, which relies more on buybacks than real sales expansion—and worries AI might replace some of its outsourced work. With Charles River’s new CEO taking the reins, investors should watch for a smooth asset deal, sustained biotech funding, and signs that drugmakers aren’t shifting data work in-house.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/6c7d83391aaa4901